Core Peptides Outlet Mazdutide 10mg (LY3305677) – Dual GLP-1 and Glucagon Receptor Agonist

Core Peptides Outlet Mazdutide 10mg (also known in clinical settings as LY3305677) is an injectable polypeptide in development as a high-potency, once-weekly dual agonist of both the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. Engineered for maximum metabolic stability and prolonged half-life, this 10mg lyophilized peptide is at the forefront of obesity and type 2 diabetes research in 2026.

By mimicking two endogenous gut hormones, Mazdutide targets glucose control and energy balance through a sophisticated, synergistic metabolic approach that exceeds the capabilities of standard mono-therapy GLP-1 analogues.

Advanced Multi-Pathway Metabolic Synergism (GLP-1/GCG)

Mazdutide operates through a dual-agonist approach that differs significantly from first-generation weight-loss peptides:

• GLP-1 Pathway (Appetite & Gastric Control): Mazdutide stimulates the GLP-1 receptor to promote satiety, slow gastric emptying, and enhance glucose-dependent insulin secretion. This established mechanism directly modulates post-meal glucose spikes and reduces voluntary caloric intake.

• Glucagon (GCG) Pathway (Energy Expenditure & Lipolysis): The key differentiator of Mazdutide is its potent activation of the glucagon receptor. This agonist pathway is crucial for increasing resting energy expenditure (thermogenesis) and directly accelerating adipose tissue lipolysis (fat breakdown). Unlike standard therapies that often lead to metabolic adaptation and stagnation, the glucagon component ensures sustained energy output.

• Systemic Synergy: By balancing appetite suppression with increased fat oxidation, Mazdutide is studied for its potential to produce profound weight reduction while supporting muscle preservation and metabolic rate.

Key Research Areas and Physiological Applications

In clinical and laboratory models, the dual action of Core Peptides Mazdutide 10mg is evaluated across multiple critical metabolic fronts:

• Next-Generation Weight Management: Targeted for research into significant, sustainable weight reduction exceeding the outcomes of standalone GLP-1 mimetics.

• Glycemic Control (Type 2 Diabetes): Evaluated for its ability to lower HbA1c, stabilize blood glucose levels, and improve overall insulin sensitivity.

• Lipid and Cholesterol Regulation: Investigated for its impact on reducing liver fat accumulation (NAFLD/NASH) and optimizing lipid profiles (LDL and Triglycerides).

• Cardiovascular Health: Research indicates potential systemic benefits derived from enhanced fat loss and metabolic efficiency, supporting studies into long-term cardiovascular risk reduction.

Specifications and Quality Verification

Every 10mg vial is synthesized to meet pharmaceutical standards.

• Active Peptide: Mazdutide (LY3305677)

• Concentration: 10 mg per vial

• Form: Lyophilized (Freeze-Dried) powder

• Purity: >99.0% verified by HPLC (High-Performance Liquid Chromatography) analysis.

• Verification: Certificate of analysis for your specific batch.

Reconstitution and Research Protocols

Core Peptides Mazdutide 10mg is designed specifically for once-weekly subcutaneous administration in laboratory models.

• Recommended Reconstitution: Reconstitute with Bacteriostatic Water or Sterile Saline immediately prior to use to ensure stability and sterility for multiple administrations.

• Standard Starting Protocol: Research typically begins with a low titration phase (e.g., 0.5 mg to 1.0 mg weekly) before advancing to a maintenance dosage.

• Maintenance Threshold: In metabolic studies, therapeutic maintenance levels often range from 3.0 mg to 9.0 mg per week, with 10mg vials facilitating precise escalation.

• Storage and Stability: Store lyophilized vials at -20°C for up to 3 years. Once reconstituted, vials must be kept refrigerated at 2°C–8°C and should be used within 30 days to maintain maximum potency.